200-070-4

Applied Filters:

Keyword:'200-070-4'

Showing 1-1 of 1 result for "200-070-4" within Papers

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.

Rodney Dawson et al.

Lancet (London, England), 385(9979), 1738-1747 (2015-03-22)

New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 weeks

Page 1 of 1